Absci (ABSI) Depreciation & Amortization (CF) (2020 - 2026)
Absci (ABSI) reported Depreciation & Amortization (CF) of $2.7 million for Q1 2026, down 11.2% on a YoY basis from $3.1 million in Q1 2025, and down 3.54% sequentially from $2.8 million in Q4 2025.
Absci (ABSI) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Absci (ABSI) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $2.7 million in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 11.2% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $11.4 million (down 12.63% YoY), and the FY2025 full-year result was $11.7 million, down 12.3% from the prior year.
- Depreciation & Amortization (CF) retreated to $2.7 million in Q1 2026, from $2.8 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.6 million in Q4 2022 to a low of $2.7 million in Q1 2026.
- A 5-year average of $3.2 million and a median of $3.4 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) jumped 510.5% in 2022 and decreased 15.29% in 2025, its largest moves.
- Tracing ABSI's Depreciation & Amortization (CF) over 5 years: stood at $3.6 million in 2022, then fell by 2.84% to $3.5 million in 2023, then retreated by 7.18% to $3.2 million in 2024, then declined by 12.55% to $2.8 million in 2025, then slipped by 3.54% to $2.7 million in 2026.
- Business Quant data shows ABSI's Depreciation & Amortization (CF) at $2.7 million in Q1 2026, $2.8 million in Q4 2025, and $2.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Absci | 1.23 Bn | 1.11 Bn | - | 2.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.73 Mn |
| Mar 31, 2026 | 2.73 Mn |
| Dec 31, 2025 | 2.83 Mn |
| Dec 31, 2025 | 2.83 Mn |
| Sep 30, 2025 | 2.84 Mn |
| Sep 30, 2025 | 2.84 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Mar 31, 2025 | 3.07 Mn |
| Mar 31, 2025 | 3.07 Mn |
| Dec 31, 2024 | 3.23 Mn |
| Dec 31, 2024 | 3.23 Mn |
| Sep 30, 2024 | 3.36 Mn |
| Sep 30, 2024 | 3.36 Mn |
| Jun 30, 2024 | 3.38 Mn |
| Jun 30, 2024 | 3.38 Mn |
| Mar 31, 2024 | 3.42 Mn |
| Mar 31, 2024 | 3.42 Mn |
| Dec 31, 2023 | 3.48 Mn |
| Dec 31, 2023 | 3.48 Mn |